Ocular Therapeutix (OCUL) Faces Ongoing Losses Amid Bullish Revenue Growth Expectations

Ocular Therapeutix (OCUL) is expected to remain unprofitable for the next three years with a negative net profit margin, despite forecasted annual revenue growth of 52.8%. The company's share price trades below its calculated fair value but is expensive on price-to-sales multiples. Ongoing losses, dilution risks, and recent insider selling add to concerns about management's confidence in long-term upside.